SOLVONIS THERAPEUTICS PLC (SVNS.L)
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
drawn.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in GBP.
Every figure as a table ›
Revenue Annual
0
200K
400K
600K
FY22: 542K FY23: 587K FY24: 0 FY25: 0 FY22
FY23
FY24
FY25
Gross Profit Annual
0
150K
300K
450K
FY22: 300K FY23: 258K FY24: 0 FY22
FY23
FY24
Operating Income Annual
-6M
-4M
-2M
0
2M
4M
6M
FY22: -2.7M FY23: -3.1M FY24: -1.4M FY25: -5.7M FY22
FY23
FY24
FY25
Net Income Annual
-6M
-4M
-2M
0
2M
4M
6M
FY22: -2.7M FY23: -3.1M FY24: -1.6M FY25: -5.7M FY22
FY23
FY24
FY25
Cost of Revenue Annual
Nothing in this filer's XBRL supports this figure for the periods asked
for, so there is nothing to draw. That is a gap in the filing, not a zero.
Operating Cash Flow Annual
-4.5M
-3M
-1.5M
0
1.5M
3M
4.5M
FY22: -2.4M FY23: -1.2M FY24: -1.1M FY25: -3.3M FY22
FY23
FY24
FY25
Free Cash Flow Annual
-4.5M
-3M
-1.5M
0
1.5M
3M
4.5M
FY22: -3.1M FY23: -1.5M FY24: -1.1M FY22
FY23
FY24
Operating cash flow minus capital expenditure.
Shares Outstanding Annual
Nothing in this filer's XBRL supports this figure for the periods asked
for, so there is nothing to draw. That is a gap in the filing, not a zero.
EPS TTM
Nothing in this filer's XBRL supports this figure for the periods asked
for, so there is nothing to draw. That is a gap in the filing, not a zero.